Adaptimmune Therapeutics (ADAP) Company Revenue

Adaptimmune (ADAP) maintains a stable free cash flow driven by partnership payments and its leadership in T-cell therapy. However, intense competition in oncology and manufacturing costs create risks. This chart on the GURU.Markets platform illustrates the company's operating revenue dynamics, where 0.00 reflects the metric's baseline. This confirms the company's status as a medical leader following the successful launch of Tecelra.

ADAP - adaptimmune.com Company Sales over the range 07/04/2022 - 11/15/2025

Comprehensive metric breakdowns and analytics for Adaptimmune Therapeutics plc (ADAP)

- market price and analyst price targets:

Market Price Adaptimmune Therapeutics PLC|ADAP - Price Target Chart

- market capitalization details:

Market Value Adaptimmune Therapeutics plc|ADAP - Total Company Value

- book capitalization information:

Net Assets per Single Share Adaptimmune Therapeutics|ADAP - Company Net Assets|Market Value to Book Value adaptimmune.com|ADAP - Company Total Assets

- company liabilities and liquidity data:

- earnings and market ratios statistics:

ADAP - Net Income|Future Net Profit Adaptimmune|ADAP - P/E Multiple|Future Price to Earnings Multiple Adaptimmune Therapeutics PLC|ADAP - PEG Multiple|Company Value to EBITDA Adaptimmune Therapeutics plc|ADAP - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Adaptimmune Therapeutics|ADAP - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth adaptimmune.com|ADAP - Earnings per share growth in current year|Net earnings per share change forecast for next year Adaptimmune

- issuer revenue and sales details:

ADAP - Company Sales|Company Expected Sales Volume Adaptimmune Therapeutics PLC|ADAP - P/S Multiple|Forward P/S Multiple Adaptimmune Therapeutics plc

Comprehensive company analysis:adaptimmune.com ADAP

Mass-produced product of Adaptimmune Therapeutics

The scale of operations at Adaptimmune (ADAP) determines its market viability. This metric measures the aggregate cash flow from product sales, reflecting the issuer's actual commercial expansion. Investors distinguish fundamental strength from market noise by evaluating the production efficiency of personalized medicines and the success of the SPEAR platform. The trend in the company's sales figures confirms how successfully therapeutic innovations are being converted into sustainable financial results.

Key competitors